US 12251440
Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
granted A61KA61K2039/507A61K39/00
Quick answer
US patent 12251440 (Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments) held by REGENERON PHARMACEUTICALS, INC. expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Mar 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 16
- CPC classes
- A61K, A61K2039/507, A61K39/00, A61K39/15, A61K39/395